Pharma Stock Roundup: NVS, ABBV M&A Deals, FDA Nod to RHHBY, PFE Drugs
Novartis NVS and AbbVie ABBV announced small M&A deals. The FDA approved the expanded use of Pfizer’s PFE cancer drug Adcetris and a tablet formulation of Roche’s R ...
Nuvation Bio: Pending Approval Shot In ROSL+ NSCLS Looks A Major Upside Catalyst
Nuvation has a best-in-class lung cancer drug that could be approved in the US in June. Read why I'm bullish on the stock ...
Roche upgraded to Buy from Neutral at UBS
UBS upgraded Roche (RHHBY) to Buy from Neutral with a price target of CHF 338, up from CHF 300. The company offers sustainable growth with ...
UBS lifts Roche stock rating to Buy, raises target to CHF338
UBS analyst Matthew Weston upgraded Roche Holding (OTC:RHHBY) stock from Neutral to Buy, adjusting the price target to CHF 338.00, up from the previous CHF 300.00. The upgrade comes as the stock ...
Zacks Investment Research on MSN2d
Biogen's Q4 Earnings & Sales Beat, 2025 EPS Guidance Disappoints
Biogen BIIB reported fourth-quarter 2024 adjusted earnings per share (EPS) of $3.44, which beat the Zacks Consensus Estimate ...
Is Roche Holding AG (RHHBY) The Best Annual Dividend Stock To Buy Now?
We recently published a list of 10 Best Annual Dividend Stocks To Buy Now. In this article, we are going to take a look at ...
Celldex Therapeutics: Will They Get It Right After A Decade Of Failures?
Celldex has a strong cash position with a runway of 13-14 quarters, bolstered by a $424 million secondary offering in March 2024. Learn more on CLDX stock here.
10 Best Annual Dividend Stocks To Buy Now
In this article, we discuss 10 Best Annual Dividend Stocks To Buy Now.
Recursion Pharmaceuticals’ (RXRX) AI Approach to Drug Discovery Shows Progress
Recursion Pharmaceuticals (RXRX) is a clinical-stage biotechnology company utilizing artificial intelligence to expedite drug ...